Handelsavisen
prelaunch
Companies Healthcare 6446.TW
64
6446.TW TWSE Biotechnology & Medical Research

6446.Tw

$862,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,15 %
Op margin
31,5 %
ROE
15,8 %
Net margin
32,3 %
Debt / equity
0,03
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.

Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY10 analysts
8 buy2 hold0 sell
Avg 12m price target774,86

Analyst recommendations

10 analysts · consensus Buy
Buy8
Hold2
Sell0
12-month price target
774,86
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
10 analysts · indicative
Ownership
not yet wired
Profitability
15,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6446.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6446.TW. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong capital structure with a debt-to-equity ratio of 0.03, indicating a low reliance on debt financing. Its liquidity position is characterized by a current ratio of 6.2, suggesting a robust ability to meet short-term obligations. The company's free cash flow of 3,153,891,000 TWD supports its operational flexibility and potential for reinvestment or shareholder returns.

    Profitability metrics show a return on equity of 15.78% and a return on assets of 13.49%, both of which are strong indicators of efficient asset utilization and profitability. These figures are in line with the industry's preferred metrics, suggesting the company is performing at or above the industry median in terms of profitability and returns.

    The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn.

    Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's capital expenditure of -1,923,704,000 TWD indicates a reduction in investment in physical assets, which may reflect a strategic shift or a focus on optimizing existing resources.

    The company faces a medium liquidity risk, as noted in its risk assessment, and a low dilution risk, suggesting that the company is not expected to issue additional shares in the near term. The risk assessment also highlights that the company has a negative net cash position after accounting for total debt, which could impact its financial flexibility.

    Recent events, as reflected in the company's financial filings, indicate a stable financial position with no major adverse events reported in the latest period. The company's financial health is supported by strong operating cash flow and a solid equity base.

    Key takeaways
    • The company has a strong capital structure with a low debt-to-equity ratio and a high current ratio.
    • Profitability metrics are robust, with a return on equity and return on assets that are in line with industry standards.
    • The company's revenue is concentrated in a single segment, which may increase its exposure to market-specific risks.
    • The company is projected to maintain a stable growth trajectory with no significant changes in revenue expected in the next fiscal year.
    • The company faces a medium liquidity risk and a low dilution risk, indicating a stable financial position.
    • **margin_outlook_rationale**: The company's gross profit margin is expected to remain stable, supported by its strong operating income and net income.
    • **rd_outlook_rationale**: The company's research and development outlook is not explicitly provided, but its capital expenditure suggests a focus on optimizing existing resources.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $862,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $31.98B
    Net cash
    -$856.0M
    Current ratio
    6.2
    Debt / equity
    0.0
    ROA
    13.5%
    ROE
    15.8%
    Cash conversion
    105.0%
    CapEx / revenue
    -12.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    22,96
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    10
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-06 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate22,96
    Revenueno estimateno estimate24,2B TWD
    Operating incomeno estimateno estimate9,8B TWD
    Full-year consensus mean (period as reported by source) · consensus in TWD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution10 analysts
    Strong buy3
    Buy5
    Hold2
    Sell0
    Strong sell0
    12-month price target$774,86 · Median $820,00
    Low $550,00High $1 090,00
    Operating income · consensus9,8B TWD
    EPS surprise
    −40,8 %
    reported vs consensus · miss
    Revenue surprise
    −35,3 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$550,00
    Mean$774,86
    Median$820,00
    High$1 090,00
    Spot$862,00
    −10.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin31,5 %Above P75
    Net Margin32,3 %Above P75
    ROE15,8 %Above P75
    Capex / Rev-12,3 %Below median
    D/E0,03Below median
    Cash Conv1,05Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 6446.TW Market data — financials · 2026-05-27
    • PharmaEssentia Corp Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6446.TWCanonical
    TWSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage